| Term 
 | Definition 
 
        | aka acetylsalicylic acid Salicylate
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | aka Votaren XR Nonselective NSAID
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | aka Advil, Motrin IB Nonselective NSAID
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | aka Toradol (Canada) Nonselective NSAID
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | aka Aleve, Naprosyn Nonselective NSAID
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | aka Celebrex Selective NSAID
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | aka Tylenol, paracetamol (in other countries), Ofirmev (IV) miscellaneous
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | natural product contains salicylate
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | aka Acetadote administered IV
 antidote for acetaminophen
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | drug that interferes with the clotting cascade - does not dissolve clots, just keeps them from forming |  | 
        |  | 
        
        | Term 
 
        | antiplatelet drug/platelet inhibitor |  | Definition 
 
        | suppresses platelet activation and aggregation |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | antiplatelet drug or anticoagulant (misleading) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | drug that actually dissolves clots |  | 
        |  | 
        
        | Term 
 
        | Mechanism of action: aspirin |  | Definition 
 
        | decrease PG synthesis by inhibiting COX 1 & 2 irreversibly affects peripheral and central (CNS)
 |  | 
        |  | 
        
        | Term 
 
        | Mechanism of action: acetaminophen |  | Definition 
 
        | decrease PG synthesis by inhibiting COX 1 & 2 weakly in the CNS decrease PG synthesis by inhibiting COX 3 strongly in the CNS
 |  | 
        |  | 
        
        | Term 
 
        | Mechanism of action: nonselective NSADS |  | Definition 
 
        | decrease PG synthesis by inhibiting COX 1 & 2, reversibly peripherally and centrally
 |  | 
        |  | 
        
        | Term 
 
        | mechanism of action: selective NSAIDS |  | Definition 
 
        | decrease PG synthesis by inhibiting primarily COX 2, reversibly peripherally and centrally
 |  | 
        |  | 
        
        | Term 
 
        | which nonopioid analgesic is not high protein binding? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what are the absorption issues for nonopioid analgesics? |  | Definition 
 
        | no major issues - may take with food if desired |  | 
        |  | 
        
        | Term 
 
        | how does ibuprofen affect fetus/neonates? |  | Definition 
 
        | not detected in breastmilk in significant amounts, but crosses placenta |  | 
        |  | 
        
        | Term 
 
        | at what point should pregnant women change their NSAID use? |  | Definition 
 
        | Avoid NSAIDs in the second half of pregnancy |  | 
        |  | 
        
        | Term 
 
        | where are the nonopioid analgesics metabolized |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | when is a person at risk for analgesic nephropathy? |  | Definition 
 
        | with chronic high-dose NSAID/acetaminophen use |  | 
        |  | 
        
        | Term 
 
        | how are nonopioid analgesics excreted |  | Definition 
 
        | renally, some of the excretion is of active drug |  | 
        |  |